High N6 ‐methyladenosine‐activated TCEAL8 mRNA is a novel pancreatic cancer marker
Cancer Science · 2024
DOI: 10.1111/cas.16152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Tomoaki Hara und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Osa…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenosine, Biomarkers, Tumor, RNA, Messenger. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takahashi Industrial and Economic Research Foundation, Mitsubishi Foundation, Japan Science and Technology Agency.
Abstract (Originalsprache)
N6‐methyladenosine (m6A) is an RNA modification involved in RNA processing and widely found in transcripts. In cancer cells, m6A is upregulated, contributing to their malignant transformation. In this study, we analyzed gene expression and m6A modification in cancer tissues, ducts, and acinar cells derived from pancreatic cancer patients using MeRIP‐seq. We found that dozens of RNAs highly modified by m6A were detected in cancer tissues compared with ducts and acinar cells. Among them, the m6A‐activated mRNA TCEAL8 was observed, for the first time, as a potential marker gene in pancreatic cancer. Spatially resolved transcriptomic analysis showed that TCEAL8 was highly expressed in specific cells, and activation of cancer‐related signaling pathways was observed relative to TCEAL8‐negative cells. Furthermore, among TCEAL8‐positive cells, the cells expressing the m6A‐modifying enzyme gene METTL3 showed co‐activation of Notch and mTOR signaling, also known to be involved in cancer metastasis. Overall, these results suggest that m6A‐activated TCEAL8 is a novel marker gene involved in the malignant transformation of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
- Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
- Prophoenix Division, Food and Life-Science Laboratory, IDEA Consultants, Inc., Osaka, Osaka, Japan.
- Kyowa-kai Medical Corporation, Kawanishi, Hyogo, Japan.
- Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
ORCID-Profile: Yu Takeda, Daisaku Yamada, Hidenori Takahashi, Hidetoshi Eguchi, Hideshi Ishii
Förderung
- Takahashi Industrial and Economic Research Foundation
- Mitsubishi Foundation
- Japan Science and Technology Agency
Zitieren
APA
Hara, T., Meng, S., Sato, H., Tatekawa, S., Sasaki, K., Takeda, Y., Tsuji, Y., Arao, Y., Ofusa, K., Kitagawa, T., Yamada, D., Takahashi, H., Kobayashi, S., Motooka, D., Suzuki, Y., Rennie, S., Uchida, S., Mori, M., Ogawa, K., …, & Ishii, H. (2024). High N6 ‐methyladenosine‐activated TCEAL8 mRNA is a novel pancreatic cancer marker. Cancer Science. https://doi.org/10.1111/cas.16152
Vancouver
Hara T, Meng S, Sato H, Tatekawa S, Sasaki K, Takeda Y, et al. High N6 ‐methyladenosine‐activated TCEAL8 mRNA is a novel pancreatic cancer marker. Cancer Science. 2024. doi:10.1111/cas.16152
BibTeX
@article{Hara2024,
author = {Hara, Tomoaki and Meng, Sikun and Sato, Hiromichi and Tatekawa, Shotaro and Sasaki, Kazuki and Takeda, Yu and Tsuji, Yoshiko and Arao, Yasuko and Ofusa, Ken and Kitagawa, Toru and Yamada, Daisaku and Takahashi, Hidenori and Kobayashi, Shogo and Motooka, Daisuke and Suzuki, Yutaka and Rennie, Sarah and Uchida, Shizuka and Mori, Masaki and Ogawa, Kazuhiko and Doki, Yuichiro and Eguchi, Hidetoshi and Ishii, Hideshi},
title = {High N6 ‐methyladenosine‐activated TCEAL8 mRNA is a novel pancreatic cancer marker},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16152}
}
EUVIMED